4/A: Protagonist Therapeutics CEO Executes Stock Option Plan

CEO Dinesh V. Patel exercised 75,000 stock options and sold the resulting shares under a pre-established 10b5-1 trading plan.

Summary

• Dinesh V. Patel, President and CEO of Protagonist Therapeutics, exercised 75,000 stock options at a strike price of $21.58.
• Following the exercise, the CEO sold the 75,000 shares at a weighted average price of $100.12 per share.
• The transactions were executed on May 12, 2026, pursuant to a Rule 10b5-1 trading plan adopted on January 30, 2026.
• The filing is an amendment to clarify the existence of the 10b5-1 plan, which was omitted in the original filing.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing; the sale is routine and pre-planned, and the amendment only serves to correct a disclosure oversight.

Positives

• The transaction was conducted under a pre-planned 10b5-1 arrangement, indicating the sale was not based on non-public information.
• The CEO retains a significant beneficial ownership of 523,478 shares following the transaction.

Negatives

• The original filing required an amendment due to an administrative oversight regarding the disclosure of the 10b5-1 plan status.

Risks

• The CEO's remaining holdings are subject to market volatility and the company's future performance.

Future Outlook

No specific forward-looking guidance regarding company operations was provided in this filing.

Management Comments

• The reporting person confirmed that the transactions were effected pursuant to a 10b5-1 plan adopted on January 30, 2026.

Industry Context

StockSavvy.ai notes that executive stock sales under 10b5-1 plans are standard practice in the biotechnology sector, allowing insiders to diversify holdings while mitigating concerns regarding potential insider trading.

Comparison to Industry Standards

• The use of 10b5-1 plans is a standard governance practice for executives at mid-cap biotech firms like Protagonist Therapeutics.
• The sale price reflects a significant appreciation from the exercise price, consistent with successful growth-stage biopharma performance.

Corporate Governance

Stakeholder Impact

• Shareholders should note the CEO's continued significant equity stake in the company.

Next Steps

• No further actions or milestones were disclosed in this filing.

Key Dates

Keywords

Protagonist Therapeutics, PTGX, Insider Trading, 10b5-1, Executive Compensation, Stock Options